AQW051   

GtoPdb Ligand ID: 7371

Compound class: Synthetic organic
Comment: AQW 051 is an α7 nicotinic acetylcholine receptor (nAChR) agonist from Novartis for the oral treatment of cognitive deficits in schizophrenia, Alzheimer's, and Parkinson's diseases. Structure first disclosed at March 2014 ACS meeting. The (3S) version is CID 71553840
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 25.36
Molecular weight 294.17
XLogP 3.57
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES Cc1ccc(cc1)c1ccc(cn1)OC1CN2CCC1CC2
Isomeric SMILES Cc1ccc(cc1)c1ccc(cn1)O[C@H]1CN2CCC1CC2
InChI InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
InChI Key NPDLTEZXGWRMLQ-IBGZPJMESA-N
Bioactivity Comments
AQW051 demonstrates high affinity for nAChR α7 as a potent agonist [2]. Analogs have been published in a series of patents (but without SAR tables) including [1] where this is example B5.
Selectivity at ion channels
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
nicotinic acetylcholine receptor α7 subunit Hs Agonist Agonist 7.6 pKi - 2
pKi 7.6 (Ki 2.7x10-8 M) [125I]α- bungarotoxin binding assay [2]